Does the false‐negative rate for 1 or 2 negative sentinel nodes after neo‐adjuvant chemotherapy translate into a high local recurrence rate?

Autor:	Salvatore Nardello, Philip Albaneze, Mengying Deng, John M. Daly, Elin R. Sigurdson, Nicole E Sharp, Nicole M. Melchior, Darren B. Sachs, Allison A. Aggon, Richard J. Bleicher
Rok vydání:	2021
Předmět:	medicine.medical_specialty medicine.medical_treatment Breast Neoplasms Gastroenterology Article 030218 nuclear medicine & medical imaging law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine Biopsy Internal Medicine Humans Medicine Prospective Studies Stage (cooking) Neo adjuvant chemotherapy Chemotherapy medicine.diagnostic_test Sentinel Lymph Node Biopsy business.industry Cancer Sentinel node medicine.disease Neoadjuvant Therapy Tumor registry Oncology Lymphatic Metastasis 030220 oncology & carcinogenesis Axilla Lymph Node Excision Female Surgery Lymph Nodes Neoplasm Recurrence Local business
Zdroj:	Breast J
ISSN:	1524-4741 1075-122X
DOI:	10.1111/tbj.14206
Popis:	BACKGROUND: Prospective trials demonstrate that sentinel node (SN) biopsy after neoadjuvant chemotherapy (NACT) has a significant false negative rate (FNR) when only 1 or 2 SNs are removed. It is unknown whether this increased FNR correlates with an elevated risk of recurrence. METHODS: Tumor Registry data at an NCI-designated Comprehensive Cancer Center were reviewed from 2004-2018 for patients having a negative SN biopsy after NACT. RESULTS: Among 190 patients with histologically negative nodes after NACT having 1 (n=42), 2 (n=46), and ≥3 (n=102) SNs, axillary recurrences occurred in 7.14%, 0% and 1.96% (p=0.09), breast recurrences occurred in 2.38%, 6.52% and 0.98% (p=0.12), and distance recurrences occurred in 16.67%, 8.70%, 7.84% (p=0.27), respectively. Time to first recurrence did not differ by SN count (p=0.41). After adjustment for age, race, clinical stage and receptor status, there were no differences in the rates of axillary (p=0.26), breast (p=0.44), or distance recurrence (p=0.24) by numbers of SNs harvested. Median follow up was 46.8 months. CONCLUSIONS: Despite higher post-NACT FNRs reported in randomized trials for patients having
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4534887322feb298583e6524d7ae95f4 https://doi.org/10.1111/tbj.14206 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.